Introduction
T here is controversy about many aspects of the metabolic syndrome. This controversy concerns the definition of the metabolic syndrome, the diagnostic criteria used to define it, its aetiology, its usefulness and even whether it exists at all. Diabetes Vasc Dis Res 2007;4(suppl 2):S1-S3 doi:10.3132/dvdr.2007.017
The concept of the metabolic syndrome is not a modern concept. It began in the 1920s when Kylin 1 and Marañon 2 pointed out the co-existence of hyperglycaemia, hyperuricaemia and hypertension. This definition was extended in the 1940s by the elder and younger Vague 3 to include fat distribution and central obesity, and then Crepaldi 4 in the 1960s described dyslipidaemia as an additional component.
The modern era started with Gerald Reaven's definition of Syndrome X in 1988: 5 this was defined as a clustering of resistance to insulin-stimulated glucose uptake, glucose intolerance, hyperinsulinaemia, raised very-low density lipoprotein-triglyceride (VLDL-TG), low levels of high-density lipoprotein cholesterol (HDL-C) and hypertension. However, Reaven's pathological construct was based on insulin resistance, and is not necessarily what is meant by metabolic syndrome.
Over the next 10 years, this construct was studied and various names were coined to describe it. The most colourful is perhaps the luxus syndrome -a good name for it, indicating that eating too much and exercising too little are fundamental to the origins of the metabolic syndrome. During this period a shift in focus has occurred away from insulin resistance and towards a greater emphasis on obesity. This change needs to be borne in mind as the usefulness of this concept is evaluated.
Definitions of the metabolic syndrome
Metabolic syndrome may be defined as a cluster of risk factors for diabetes mellitus and cardiovascular disease which occurs more often than by chance alone. Insulin resistance syndrome, by contrast, is a pathophysiological construct with insulin resistance as a key underlying factor. Insulin resistance syndrome and metabolic syndrome do not equate completely.
The main controversy surrounding the metabolic syndrome regards its possible definition and diagnostic criteria. Table 1 shows definitions of metabolic syndrome produced by the World Health Organization (WHO), 6 the European Group for the study of Insulin Resistance (EGIR) 7 and the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III. 8 The WHO definition specified that insulin resistance had to be defined using a clamp. This specification made the definition largely impractical, unfortunately. Impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) were considered acceptable surrogates. Raised blood pressure, raised triglycerides (TG) and low levels of HDL-C were also used as criteria in the WHO definition. There was uncertainty about whether to use the waist:hip ratio (WHR) or the body mass index (BMI) as a measure of weight, however.
The EGIR definition required measurement of fasting insulin. It used similar cutoff points for blood pressure, glucose and lipids but introduced waist circumference as a risk factor to be included in the cluster making up metabolic syndrome.
The NCEP definition gave more emphasis perhaps to cardiovascular risk factors than to blood glucose and insulin. Three from five of the features listed had to be present for the diagnosis to be made, and insulin resistance was not specified in part because its measurement was believed to be an invasive investigation that a primary care physician would be unlikely to carry out. The waist circumference specified in this definition of the metabolic syndrome was larger than that in the WHO and EGIR definitions, for pragmatic reasons: if the waist cutoff had been 94 cm, an unacceptably high number of the population would have been included in the definition.
The International Diabetes Federation (IDF) consensus meeting in 2004 brought together individuals with different viewpoints. The aim was to establish a unified diagnostic working tool and to highlight the areas where more knowledge was needed. The criteria included in this definition are shown in table 1 9 and compared with the definitions that preceded the IDF consensus definition. In brief, insulin resistance was agreed to be a key component but was not included since it is not easily measured. The new American Diabetes Association (ADA) definition for IFG of 5.6 mmol/L was adopted; 10 the same blood pressure and lipid cutoffs ACADEMIC DEBATE The metabolic syndrome: setting the scene. The pros S2 DIABETES AND VASCULAR DISEASE RESEARCH used in the NCEP definition were used; and European cutoffs for waist circumference were used. Central obesity was agreed to be a key component, and it was recognised that this needed to be ethnically specific.
The American Heart Association (AHA) has updated its recommendations, modifying and clarifying some of the issues surrounding the NCEP definition. 11 The levels of risk factors that need to be met for diagnosis of the metabolic syndrome are: • TG 150 mg/dL (1.7 mmol/L) or higher • HDL-C below 40 mg/dL (1.03 mmol/L) in men or 50 mg/dL (1.29 mmol/L) in women • BP above 130/85 mmHg (or treatment for high blood pressure) • Fasting glucose equal to or above 100 mg/dL (5.6 mmol/L). The AHA also recognised that certain ethnic groups, such as some Asians, are genetically predisposed to insulin resistance and are at higher risk even when their waist circumference is not increased.
Problems with the criteria
The first problem is that the criteria need to be pragmatic, especially since they will be used in primary care worldwide. Diagnosis of metabolic syndrome has clinical relevance and is not simply a research tool.
The cutoff points for the different risk factors that cluster together to make up the metabolic syndrome are the subject of debate. Are the levels used appropriate, and are they too crude? Epidemiologists tend to think in terms of risk continua rather than dichotomies though this is not always workable in practice.
Are there any missing components from the current definitions of the metabolic syndrome? Insulin resistance might be one but regrettably, as discussed, it cannot be measured easily. Inflammatory markers and adipokines such as C-reactive protein (CRP) and interleukin-6 (IL-6) might also be components but in practical terms we cannot say much about them yet in this regard. Another area yet to be resolved is whether all components of the metabolic syndrome cluster carry equal weighting.
The rationale for the current cutoff points is clear. For waist measurement, it is the circumference above which cardiovascular disease risk factors become abnormal. (This has been shown convincingly for different ethnic groups.) For the other criteria, international experts' agreed cutoff points were taken, in particular for cardiovascular disease risk factors such as hypertension and dyslipidaemia. 8 Thus, the rationale was to a certain extent pragmatic but nonetheless the cutoff levels are sensible and rest on a solid evidence base.
The common components which cluster together are: abnormal glucose, raised blood pressure, raised triglycerides, low HDL-C, central obesity and insulin resistance. Additional components which need to be examined in detail now include CRP, fibrinogen and adiponectin. As regards genetic factors, it would be interesting to know whether there is a cluster of genes that would predispose to metabolic syndrome or increase risk of adverse outcomes.
Aetiology of metabolic syndrome
It is not known whether obesity or insulin resistance is the dominant underlying factor. Obesity, particularly visceral obesity, could be the driving force. Adipocytes are a rich source of fatty acids and a range of adipokines and cytokines, all of which could play a role in both insulin resistance and atherogenesis. On the other hand, insulin resistance could drive the defects seen in adipose tissue, muscle and the liver. Actually, almost certainly, both are involved.
Relationship between Insulin Sensitivity and Cardiovascular disease (RISC) study correlations are shown in figure 1. 12 Here, data from a large cohort of Europeans were presented by Ferrannini and colleagues. There are ACADEMIC DEBATE more and stronger correlations between abdominal obesity and components of the syndrome than between insulin resistance and components of the syndrome. These data give a hint of support to the idea that abdominal obesity is central to development of metabolic syndrome.
Usefulness
Is the concept of metabolic syndrome helpful in identifying at-risk individuals? It may be looked at as a drive towards measuring risk factor levels to pick out high-risk people. For example, data from Australia show that people with metabolic syndrome are four times more likely to develop diabetes compared to those without metabolic syndrome. 13 Telling data from Sweden which followed up individuals for 30 years showed that both total mortality and cardiovascular mortality were greater in those who had metabolic syndrome at baseline (figure 2). 14 This extremely long follow-up was essential because separation of the curves only started at about 15 years.
Thus, metabolic syndrome provides a simple diagnostic set for identifying people at increased risk of cardiovascular disease and diabetes. It identifies those at high relative risk but does not provide a measure of absolute risk. To obtain the absolute risk, it needs to be used with other risk markers such as smoking, high levels of low-density lipoprotein cholesterol (LDL-C) and a family history of heart disease to give the 'overall cardiometabolic risk'.
Conclusion
The definition of metabolic syndrome needs further refinement and it requires long-term outcome studies to evaluate the various criteria definitively. In general, however, differences of opinion surrounding the syndrome are minor. 
